Ketorolac S.A.L.F. (Ketorolac Trometamol)

Ketorolac Trometamol works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which reduces the synthesis of prostaglandins. Lower prostaglandin levels diminish inflammation and pain signaling, providing analgesic and anti‑inflammatory effects.

The specific dose and duration are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment setting. Ketorolac is typically administered as a single or limited‑course injection under medical supervision.

Ketorolac is generally avoided during pregnancy, especially in the third trimester, due to potential fetal risks. Limited data exist for breastfeeding; therefore, clinicians usually consider alternative analgesics unless the benefit outweighs the risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ketorolac is distinguished by its potent analgesic effect, often comparable to opioid analgesics for short‑term use, whereas many other NSAIDs provide milder pain relief. However, its risk profile for gastrointestinal bleeding and renal effects is higher, so it is reserved for brief treatment periods.

Ketorolac S.A.L.F. should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from light, moisture, and extreme temperatures. Do not freeze or shake the vial before use.

The product is supplied as a sterile injectable solution for intramuscular or intravenous administration. The route, injection site, and infusion rate are determined by the healthcare professional based on clinical guidelines and patient needs.

The most serious risks include severe gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and platelet dysfunction leading to abnormal bleeding. Patients should be monitored closely for these events, especially when used with other high‑risk medications.

Ketorolac should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, active gastrointestinal ulcer disease, severe renal impairment, significant bleeding disorders, and in the third trimester of pregnancy. Caution is also advised for the elderly and those on anticoagulants.